Clinical trial
Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
NCT00195286 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00195286 |
|---|---|
| Title | Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections. |
| Official title | Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Urinary Infections |
| Intervention type | Drug |
| Interventions | piperacillin/tazobactam |
| Enrollment | 180 |
| Start date | Jun 1, 2004 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Sep 25, 2009 |
| Countries | Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: